Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

New antibiotics

I R Friedland¹, I Lutsar

¹Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75235-9063, USA.

Current Opinion in Pediatrics

|April 8, 1998

Summary

This review covers three broad-spectrum antibiotics: meropenem, cefepime, and trovafloxacin. These powerful antibacterial agents are best reserved for severe infections, particularly in immunocompromised patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis.

European journal of neurology·2017

Same author

HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay.

HIV medicine·2017

Same author

An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates.

Pharmaceutical research·2014

Same author

Five-year prospective surveillance of nosocomial bloodstream infections in an Estonian paediatric intensive care unit.

The Journal of hospital infection·2013

Same author

Risk assessment of neonatal excipient exposure: lessons from food safety and other areas.

Advanced drug delivery reviews·2013

Same author

European Study of Neonatal Exposure to Excipients: an update.

International journal of pharmaceutics·2013

Area of Science:

Pharmacology
Infectious Diseases
Microbiology

Background:

Review of three distinct classes of broad-spectrum antibiotics.
Focus on meropenem, cefepime, and trovafloxacin for treating serious bacterial infections.

Purpose of the Study:

To compare the characteristics and clinical applications of meropenem, cefepime, and trovafloxacin.
To highlight the advantages and limitations of each antibiotic in pediatric and adult populations.

Main Methods:

Literature review of pharmacological properties and clinical trial data.
Comparative analysis of antibacterial spectrum, efficacy, and safety profiles.

Main Results:

Meropenem shows improved gram-negative activity and reduced seizure risk compared to imipenem, approved for children.
Cefepime (fourth-generation cephalosporin) offers broad gram-positive and gram-negative coverage, approved for adults.
Trovafloxacin (fluoroquinolone) possesses an exceptionally wide antibacterial spectrum but is still in clinical trials.

Conclusions:

Meropenem, cefepime, and trovafloxacin represent significant advancements in treating serious infections.
Judicious use is recommended, especially for immunocompromised patients and polymicrobial infections.
Availability and approval status vary, impacting clinical decision-making.

Related Experiment Videos